Review key clinical data in prostate cancer and urothelial carcinoma from ASCO 2019 with this expert analysis from Daniel P. Petrylak, MD
Drs. Todd M. Bauer, Giuseppe Giaccone, Axel Grothey, John L. Marshall, and Michael J. Pishvaian discuss the latest data on 10 key clinical biomarkers in solid tumors.
Phase III TITAN trial of apalutamide + ADT for patients with metastatic castration-sensitive prostate cancer, as reported by CCO from ASCO 2019.
Results from the phase III ENZAMET trial of enzalutamide in metastatic hormone-sensitive prostate cancer as reported by CCO from ASCO 2019
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.